Overview of medical therapy for gastroesophageal disease Amarnath Ramakrishnan, MD, Philip O Katz, MD  Gastrointestinal Endoscopy Clinics  Volume 13, Issue 1, Pages 57-68 (January 2003) DOI: 10.1016/S1052-5157(02)00105-8

Fig. 1 Healing rates of erosive esophagitis at weeks 4 and 8 comparing esomeprazole 40 and lansoprazole 30 across grades A through D LA grade erosive esophagitis. (Data from Castell et al. Am J Gastroenterol. 2002;97:575) *P = 0.0001 versus lansoprazole. Gastrointestinal Endoscopy Clinics 2003 13, 57-68DOI: (10.1016/S1052-5157(02)00105-8)

Fig. 2 Healing rates of erosive esophagitis (Y axis) in two pivotal trials submitted to the FDA comparing esomeprazole 40 mg to omeprazole 20 mg showing statistical superiority of esomeprazole to omeprazole in doses shown. (Data from Kahrilas et al. Aliment Pharmacol Ther. 2000;14:1249–58; Richter et al. Am J Gastroenterol. 2001;96:656–65) *P ≤ 0.05. †P < 0.001 versus omeprazole. Gastrointestinal Endoscopy Clinics 2003 13, 57-68DOI: (10.1016/S1052-5157(02)00105-8)